TFF Pharmaceuticals Reports Continued Progress Across Programs in Corporate Update

~ Continued clinical progress with lead compound Voriconazole Inhalation Powder, to treat invasive pulmonary aspergillosis (IPA) ~ Tacrolimus Inhalation Powder for immunosuppression in transplant medicine expected to begin Phase 1 dosing in Q1-2020 ~ Initiates collaboration and feasibility agreements with major pharmaceutical and biopharmaceutical companies

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here